Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV – Get Free Report)’s stock price fell 19.9% on Thursday . The company traded as low as $0.67 and last traded at $0.67. 1,616 shares were traded during trading, an increase of 40% from the average session volume of 1,156 shares. The stock had previously closed at $0.84.
Mosaic ImmunoEngineering Trading Down 3.0 %
The firm has a market capitalization of $4.71 million, a P/E ratio of -4.33 and a beta of 0.27. The business’s 50 day simple moving average is $0.89 and its two-hundred day simple moving average is $0.89.
Mosaic ImmunoEngineering Company Profile
Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.
Recommended Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- How to Profit From Value Investing
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- 3 REITs to Buy and Hold for the Long Term
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
